2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease
B Besse, A Adjei, P Baas, P Meldgaard, M Nicolson, L Paz-Ares, M Reck, E F Smit, K Syrigos, R Stahel, E Felip, S Peters, Panel Members, ESMO, Rolf Stahel, Enriqueta Felip, Solange Peters, Keith Kerr, Benjamin Besse, Johan Vansteenkiste, Wilfried Eberhardt, Martin Edelman, Tony Mok, Ken O'Byrne, Silvia Novello, Lukas Bubendorf, Antonio Marchetti, Paul Baas, Martin Reck, Konstantinos Syrigos, Luis Paz-Ares, Egbert F Smit, Peter Meldgaard, Alex Adjei, Marianne Nicolson, Lucio Crinò, Paul Van Schil, Suresh Senan, Corinne Faivre-Finn, Gaetano Rocco, Giulia Veronesi, Jean-Yves Douillard, Eric Lim, Christophe Dooms, Walter Weder, Dirk De Ruysscher, Cecile Le Pechoux, Paul De Leyn, Virginie Westeel, B Besse, A Adjei, P Baas, P Meldgaard, M Nicolson, L Paz-Ares, M Reck, E F Smit, K Syrigos, R Stahel, E Felip, S Peters, Panel Members, ESMO, Rolf Stahel, Enriqueta Felip, Solange Peters, Keith Kerr, Benjamin Besse, Johan Vansteenkiste, Wilfried Eberhardt, Martin Edelman, Tony Mok, Ken O'Byrne, Silvia Novello, Lukas Bubendorf, Antonio Marchetti, Paul Baas, Martin Reck, Konstantinos Syrigos, Luis Paz-Ares, Egbert F Smit, Peter Meldgaard, Alex Adjei, Marianne Nicolson, Lucio Crinò, Paul Van Schil, Suresh Senan, Corinne Faivre-Finn, Gaetano Rocco, Giulia Veronesi, Jean-Yves Douillard, Eric Lim, Christophe Dooms, Walter Weder, Dirk De Ruysscher, Cecile Le Pechoux, Paul De Leyn, Virginie Westeel
Abstract
To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO Consensus Conference on Lung Cancer was held on 11-12 May 2013 in Lugano. A total of 35 experts met to address several questions on non-small-cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, first-line/second and further lines of treatment in advanced disease, early-stage disease and locally advanced disease. For each question, recommendations were made including reference to the grade of recommendation and level of evidence. This consensus paper focuses on first line/second and further lines of treatment in advanced disease.
Keywords: ESMO; consensus; first line; further lines; non-small-cell lung cancer; second line.
© The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Source: PubMed